Day One Biopharmaceuticals Stock Analysis

Day Stock Analysis Notes

About 17.0% of the company shares are held by company insiders. The book value of Day One was currently reported as 5.51. The company recorded a loss per share of 0.97. Day One Biopharmaceu had not issued any dividends in recent years. Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Day One operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 94 people. To learn more about Day One Biopharmaceuticals call Jeremy MBA at 650 484 0899 or check out https://dayonebio.com.

Day One Biopharmaceu Investment Alerts

Day One Biopharmaceu Upcoming and Recent Events

Day Largest EPS Surprises

View All Earnings Estimates

Day One Environmental, Social, and Governance (ESG) Scores

Day Stock Institutional Investors

Note, although Day One's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Day Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.24 B.

Day Profitablity

The company has Profit Margin (PM) of (0.83) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.32 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.32.

Management Efficiency

Day One Biopharmaceu has return on total asset (ROA) of (0.2543) % which means that it has lost $0.2543 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1784) %, meaning that it created substantial loss on money invested by shareholders. Day One's management efficiency ratios could be used to measure how well Day One manages its routine affairs as well as how well it operates its assets and liabilities. As of the 17th of February 2025, Return On Tangible Assets is likely to drop to -0.47. In addition to that, Return On Capital Employed is likely to drop to -0.72. At this time, Day One's Net Tangible Assets are very stable compared to the past year. As of the 17th of February 2025, Other Current Assets is likely to grow to about 10.8 M, while Total Assets are likely to drop about 239.3 M.

Technical Drivers

As of the 17th of February 2025, Day One shows the Standard Deviation of 2.43, variance of 5.91, and Mean Deviation of 1.93. Day One Biopharmaceu technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.

Day One Biopharmaceu Price Movement Analysis

Day One Biopharmaceu Insider Trading Activities

Day One Outstanding Bonds

Day One Predictive Daily Indicators

Day One Corporate Filings

Day One Forecast Models

Day One's time-series forecasting models are one of many Day One's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Day One's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Day One prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Day shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Day One. By using and applying Day Stock analysis, traders can create a robust methodology for identifying Day entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Day analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Day analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Day One Biopharmaceuticals stock analysis indicators help investors evaluate how Day One stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Day One shares will generate the highest return on investment. By understating and applying Day One stock analysis, traders can identify Day One position entry and exit signals to maximize returns.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Day One Biopharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Day One. If investors know Day will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Day One listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Day One Biopharmaceu is measured differently than its book value, which is the value of Day that is recorded on the company's balance sheet. Investors also form their own opinion of Day One's value that differs from its market value or its book value, called intrinsic value, which is Day One's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Day One's market value can be influenced by many factors that don't directly affect Day One's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Day One's value and its price as these two are different measures arrived at by different means. Investors typically determine if Day One is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Day One's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.